GlassScriptPhysician profile
Rick M Hirsch
NPI 1497774954
$4,091.52
in general payments reported to CMS, 2019-2025
30 companies · $864 in 2025
The $864 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $387 · 2020: $251 · 2021: $481 · 2022: $492 · 2023: $780 · 2024: $837 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,481.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $826.37 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $354.62 | 2021-2025 | Arexvy, Trelegy Ellipta |
| Abbvie INC. | $308.00 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $274.95 | 2023-2024 | |
| Novo Nordisk INC | $263.54 | 2024-2025 | Ozempic |
| Janssen Pharmaceuticals, INC | $219.23 | 2019-2024 | Xarelto |
| Allergan, INC. | $214.39 | 2020-2021 | |
| Sanofi Pasteur INC. | $193.88 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $189.00 | 2022 | |
| Medicure Pharma INC. | $147.71 | 2023 | Zypitamag |
| Sunovion Pharmaceuticals INC. | $124.83 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $123.53 | 2021 | |
| Pfizer INC. | $92.19 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.09 | 2022-2025 | Jardiance |
| Exact Sciences Corporation | $75.96 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $74.63 | 2025 | |
| Cequr Corporation | $72.56 | 2023 | Cequr Simplicity |
| Novartis Pharmaceuticals Corporation | $63.51 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.90 | 2021-2024 | Xifaxan |
| Amgen INC. | $56.80 | 2023-2024 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $47.17 | 2021-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $37.60 | 2024 | Austedo Xr |
| Lucid Diagnostics INC. | $36.58 | 2022 | |
| Sumitomo Pharma America, INC. | $27.96 | 2023 | Gemtesa |
| Tolmar, INC. | $23.28 | 2025 | Jatenzo |
| Astellas Pharma US INC | $23.07 | 2024 | Veozah |
| Ironwood Pharmaceuticals, INC | $23.02 | 2022 | |
| Lilly USA, LLC | $20.24 | 2022 | |
| Edwards Lifesciences Corporation | $18.81 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Kowa Pharmaceuticals America, INC. | $17.10 | 2023 | Livalo, Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rick Hirsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.